Current and potential use of GLP-1R agonists: beyond type 2 diabetes
Intestinal incretins, glucagon-like peptide 1 (GLP-1), and gastric insulinotropic peptide, which are released after food ingestion, have glucoregulatory effects, which is why, in recent years, pharmacological agents with an impact similar to incretins have been developed. The results of GLP-1 and it...
Saved in:
| Main Authors: | Graciela Zambrano-Galván, Ángel González-Romero, Miguel A. Reyes-Romero, Abelardo Camacho-Luis |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Permanyer
2024-10-01
|
| Series: | Revista Mexicana de Endocrinología, Metabolismo y Nutrición |
| Subjects: | |
| Online Access: | http://www.revistadeendocrinologia.com/frame_eng.php?id=350 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of GLP-1 Receptor Agonists on Perceived Eating Behaviors in Response to Stimuli
by: Cheney C, et al.
Published: (2025-05-01) -
Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes
by: Gagik R. Galstyan, et al.
Published: (2017-10-01) -
GLP-1 and Its Role in Glycogen Production: A Narrative Review
by: Joseph Lotosky, et al.
Published: (2025-06-01) -
Glucagon-Like Peptide-1 and Hypothalamic Regulation of Satiation: Cognitive and Neural Insights from Human and Animal Studies
by: Joon Seok Park, et al.
Published: (2025-05-01) -
The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)